forumAdmin
30-11-2007, 06:27 PM
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that Biological Psychiatry published the results of a study showing VYVANSE? (lisdexamfetamine dimesylate), the first prodrug stimulant for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), provided significant efficacy in children for up to 12 hours. [click link for full article]
External site More Info here... (http://www.medicalnewstoday.com/articles/90283.php)
Please return here to comment...............
External site More Info here... (http://www.medicalnewstoday.com/articles/90283.php)
Please return here to comment...............